STUDresearch · Peptide
PEG-MGF
Also known as
Pegylated Mechano Growth Factor · PEGylated Mechano Growth Factor · PEG MGF · PEG-MGF peptide · Pegylated MGF · PEGylated MGF · Peg-MGF · PEGylated IGF-1Ec (community shorthand) · PEG-IGF-1Ec (loose forum synonym — not always the same product) · Mechano Growth Factor (pegylated form)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Mixed
SubQ / IM
Growth factors
Mixed in discussion: SubQ use and local IM placement both appear; human distribution and a multi-day half-life remain unverified.
What people say
PEG-MGF is a PEGylated MGF-fragment label used in muscle-recovery and growth discussions. It is not full-length IGF-1Ec or PEG-IGF-1. The muscle-cell research concerns an E-domain fragment, not a validated human PEG-MGF treatment.
Doses people talk about
Preserved outliers include 200–500 mcg daily charts, a 400–600 mcg tracker band and ambiguous “150 mcg/day, 2–3 times/week” wording. The latter does not establish dosing on all seven days.
How it may feel
Reports range from little change to perceived recovery or training benefit over weeks. An experimental nasal report later described immediate relaxation and quicker recovery, but involved BPC/TB-500 and unknown absorption. Site irritation and null results remain part of the record.
One workout-use accountUp to 300 mcg/day, sometimes 400 mcg/day IM
One commenter reported up to 300 mcg, sometimes 400, on consecutive PR-attempt days. Placement and perceived benefit are personal claims, not proof of local action.
Lower chart band~100–150 mcg per injection
Guides describe early tolerance checking over 1–2 weeks. Other sketches say 150 mcg/day on 2–3 days/week; that conflicting wording is preserved, not resolved into a regimen.
Main chart comparisons~200–250 / 200–400 mcg per injection
SubQ or IM discussions often pair these with 2–3 weekly doses; other summaries use 1–2 weekly doses. Daily 200–500 mcg charts conflict with this framing.
Half-life & effect duration
- Half-life in the body
- Common community estimateAbout 48–72 hours
- Other community estimates24+ hours or about 5 days
- Felt duration people report
- Nasal experimentImmediate relaxation and perceived workout recovery
- Injection reportsWorkout-related impressions and personal-record days; no consistent duration
Cycles people discuss
Charts describe 3–4, 4–6 or 4–8-week blocks; some extend to 8–10 weeks. Breaks of 2–4 or 4–6 weeks, sometimes as long as the run, are cycling lore rather than demonstrated receptor recovery or safe washout.
Timing
Community charts most often place injections two or three times weekly on training or post-workout days, commonly across four-to-six-week blocks. Other charts use daily timing, so the schedule is contested rather than established.
Stacks
LR3, DES, GH-axis agents and BPC-157/TB-500 appear in stack stories. The “two-wave” MGF-then-IGF narrative is unproven, and insulin combinations add glucose-risk uncertainty.
Watch for
Not risk-free: Missing a side effect in one log ≠ safety evidence; research-chemical framing does not erase sterility, growth-pathway, or product-identity risks.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Human PEG-MGF half-life remains unestablished in the reviewed evidence.
48–72 hours, 24+ hours and about five days are conflicting chart claims. Native-fragment minute ranges are also different, unverified contexts.
The inspected primary experiment used MGF-E in cultured cells; it cannot measure injected PEG-MGF clearance. Community schedules do not fill that gap.
- Kandalla et al. (2011): MGF-E in human muscle cell cultures (opens in a new tab)Complete abstract read through Europe PMC core API for PMID 21354439; MGF-24aa-E peptide, primary human muscle cultures, age-dependent results.Culture experiment using the E-domain fragment, not human administration or PEG-MGF pharmacokinetics. PubMed HTML was empty; actual abstract read through Europe PMC.
- PEG-MGF timing discussion and conflicting route preferences (opens in a new tab)Opening post; neerrccoo replies on workout placement and 300/400 mcg; Any-Study-3723 follow-ups preferring SubQ and describing modest recovery.Visible replies include deleted parents and collapsed branches. Unverified product and self-report; no assay, measured kinetics or systematic outcome follow-up. Local-only efficacy assertions are not adopted.
Felt duration people report
Reports describe different perceived benefits, not a reproducible duration.
A nasal experiment’s same-author update reports immediate relaxation and perceived workout recovery; injection discussion instead emphasizes workout placement and PR days.
No timed offset; nasal absorption was speculative, BPC/TB-500 were co-used, and injectable identity was unverified. These are not interchangeable routes.
- PEG-MGF timing discussion and conflicting route preferences (opens in a new tab)Opening post; neerrccoo replies on workout placement and 300/400 mcg; Any-Study-3723 follow-ups preferring SubQ and describing modest recovery.Visible replies include deleted parents and collapsed branches. Unverified product and self-report; no assay, measured kinetics or systematic outcome follow-up. Local-only efficacy assertions are not adopted.
- PEG-MGF nasal experiment with same-author update (opens in a new tab)LieWorldly4492 opening plan, later absorption-theory replies and same-author “Almost forgot to report back” update describing immediate relaxing/cognitive impressions, perceived recovery and prohibitive cost.Experimental nasal product with BPC/TB-500 co-use; actual achieved amount unspecified. Bioavailability and accumulation are poster extrapolations, not human measurements. No preparation or absorption-enhancer instructions adopted.
What people say
- Recovery / soreness: Faster bounce-back between high-volume sessions and less next-day noise are the most repeated self-reports — heavily confounded by training, sleep, food, and stacks. forum
- Training continuity: Easier adherence to progressive overload blocks when DOMS or “beat up” feel is lower in logs. forum
- Hypertrophy / size: Fuller pumps or gradual size on a surplus over multi-week runs; single-agent credit is unreliable and often shared with IGF-1 LR3, GH-axis compounds, or AAS. forum
- Satellite-cell / hyperplasia lore: Classic forum story — MGF/PEG “multiplies cells,” then IGF-1 LR3 (or training) “builds them out.” Pathway storytelling more than measured human fiber-count proof. forum
- Post-workout timing fit: Dosed after lifting to mimic natural MGF release after mechanical damage — preference and lore, not controlled timing trials. anecdote
- Vs native MGF practicality: Main popularity driver is schedule convenience (2–3× weekly vs frequent short-acting pins). forum
- Injury / strain downtime talk: Better readiness and soft-tissue recovery narratives; mixed with PT, rest, BPC/TB, and time — causality muddy. forum
- Localized / lagging-muscle talk: IM or near-muscle placement for regional repair/fullness claims — anecdotes; PEG duration undercuts pure “only this muscle” claims. forum
- Stack halo problem: Many “PEG-MGF worked” logs also run IGF-1 LR3, HGH/secretagogues, surplus calories, or AAS — attribution is unreliable. forum
- Preclinical hook: MGF-E peptide work shows increased proliferative lifespan and delayed senescence of human muscle progenitor/satellite cells in culture (often-cited Kandalla et al. 2011 class findings). lab
- Animal / loading backdrop: MGF expression and injury/loading models are cited as the science backdrop for repair talk, not as proof of gray-market PEG product outcomes. animal
Doses people talk about
- Broad per-injection band: ~100–400 mcg is the most repeated single-injection range across guides and calculators. forum
- Common working band: ~200–250 mcg per dose is the modal “standard” in many bodybuilding and peptide-protocol write-ups. forum
- Standard chart band: ~200–400 mcg per injection, often framed as the typical research-use range. forum
- Aggressive chart band: ~400 mcg per dose (sometimes 3×/week) appears as “advanced / high-volume” calculator tiers — more site and nonspecific side talk. forum
- Frequency — dominant lore: ~2–3× per week, usually on training / post-workout days, justified by multi-day PEG half-life claims (not daily native-MGF style). forum
- Frequency — lower: ~1–2× weekly at 200–400 mcg appears on some research-summary cards. forum
- Frequency — minority daily charts: Some vendor titration tables show once-daily SubQ ~200–500 mcg with multi-week step-ups (e.g., 200 → 300 → 400 → 500 mcg over ~8 weeks) — these conflict with the more common 2–3×/week PEGylated rationale and should be read as chart variance, not consensus. forum
- Example weekly structure (common write-up): ~200 mcg Mon / Wed / Fri post-exercise → ~600 mcg/week total. forum
- Calculator-style tiers (community tools): Beginner ~150 mcg 2×/week; moderate ~200 mcg 3×/week; aggressive ~400 mcg 3×/week — illustrative marketing tiers, not trial arms. forum
- Jay Campbell–class starting sketch (public guide style): ~150 mcg per day SubQ or IM into target area, 2–3×/week over ~8–10 weeks — another published community-facing variant, not a clinical standard. forum
- Reddit / forum shorthand: ~150 mcg/day, 2–3×/week is a repeated short protocol line; experienced logs sometimes push higher absolute mcg. forum
- App / self-report buckets (one community tracker sample): Median logged band ~200–400 mcg per injection; reports also span ~400–600 mcg — small-n self-report, not clinical distribution. Separately, neerrccoo in an opened 2023 Reddit discussion reports IM use during workouts on consecutive PR-attempt days, up to 300 mcg/day and sometimes 400; that is one conflicting account, not the tracker’s distribution. forum
- Split / multi-site: Bilateral split (e.g., half dose each side after leg/arm day) or multi-muscle placement after full-body sessions — minority advanced logs; total weekly mcg still matters. forum
- Guide progression claim: Some guides describe holding a working dose for 2+ weeks with acceptable tolerance before considering an increase; this is unvalidated chart logic, not a titration instruction. Their protective warning not to double a missed dose is retained. forum
- Source uncertainty: Labeled mcg ≠ verified content; PEGylation identity and potency variance confound every comparison between logs. forum
- Lower chart band: ~100–150 mcg is presented in guides as first-dose or first-1–2-week tolerance checking before mid-hundreds. This records the guide’s framing, not a validated starting dose or an instruction to progress. forum
- Single-site SubQ: Abdomen/thigh convenience for systemic framing when not chasing a lagging muscle. forum
- Weight-based research talk: ~1–5 µg/kg appears in some preclinical/“research setting” summaries — not a standard gym chart and not validated for gray-market products. animal
- Framing: Community, vendor-chart, and research-chem protocol ranges only — not medical advice, not prescriptions, not validated athletic doses. No peer-reviewed human dose-finding trial establishes a PEG-MGF hypertrophy protocol. forum
How it may feel
- Day of injection: Usually no stimulant-like buzz; awareness is mostly injection-site feel (sting, mild fullness) and whether SubQ vs IM was used. forum
- Days 1–7: Little dramatic cosmetic change; logs emphasize technique, site rotation, and whether sleep/training already explain any soreness shift. forum
- Weeks 3–4: Common reassess point on a 4–6 week block; physique or recovery anecdotes that land often start showing here if they will. forum
- Weeks 4–6: Modal cycle end for bodybuilding-style charts; size/fullness claims that stick are often reported toward the end of this window, not overnight. forum
- Weeks 6–8: Upper end of many “research protocol” cycle tables (4–8 weeks); longer continuous use has thinner public logs. forum
- Beyond ~8–10 weeks: Sparse documented open-ended use; desensitization / habit talk appears more than controlled long-run data. forum
- No useful change by ~3–4 weeks: Community advice is recheck training stimulus, calories, sleep, vial math, and product identity — not automatic jump from 200 → 400+ mcg. Opened reports are not uniform: one commenter describes workout-related benefit with IM use, while the original poster prefers SubQ and describes only some recovery benefit. In a separate nasal experiment, a different poster, LieWorldly4492, later described immediate relaxing/cognitive impressions and perceived workout recovery, but stopped short of endorsing the cost; BPC/TB-500 co-use and unknown absorbed dose prevent attribution. None provides a measured felt offset. forum
- Weeks 1–2: Recovery continuity / less next-day noise is the earliest commonly claimed signal — still confounded. Some vendor timelines also push “anti-inflammatory / mobility” framing in this window for injury-adjacent use. forum
Cycles people discuss
- Most common bodybuilding length: ~5–6 weeks on appears repeatedly in classic peptide vendor/forum protocol language. forum
- Standard modern chart band: ~4–6 weeks on, then time off. forum
- Broader research-protocol band: ~4–8 weeks on in several dosing tables. forum
- Shorter test block: ~3–4 weeks to match a mesocycle or decide if recovery feel is real before committing another vial. forum
- Longer public sketches: ~8–10 weeks on appears in some beginner guides — less common than 4–6 and thinner outcome documentation. forum
- Time off — common: ~2–4 week break after a 4–6 week run in several vendor-style write-ups. forum
- Time off — conservative lore: Mirror on-time or ≥ on-time (e.g., 4–6 weeks off) before re-run; some protocol pages push ≥4 weeks off after any multi-week block. forum
- When to run: Timed to high-volume / progressive-overload phases or injury-adjacent rehab blocks more often than deep cuts. forum
- Re-runs: Common on later bulks; no solid long-term safety database for repeated gray-market PEG-MGF cycles. forum
- Stack-length note: When paired with IGF-1 LR3, the LR3 window is often the shorter “cap” (e.g., ~3–4 weeks LR3 lore) while PEG may span a 4–6 week recovery block — schedules vary by camp. forum
- Exit / reassess flags discussed: Persistent site reactions >48–72 h, blood-sugar weirdness, unresolved headache/fatigue, or zero training/recovery signal by mid-cycle. forum
Timing
- Native MGF (community shorthand): ~5–7 minutes, sometimes “minutes to a few hours in solution,” is repeated as a reason for PEGylation. These are unverified community figures with different biological/solution contexts, not measured human clearance for every MGF fragment. forum
- Native MGF (alternate forum numbers): ~2–15 minutes class claims appear across older boards — order-of-magnitude “very short,” not a single lab PK consensus for every analog. forum
- PEG half-life claims (common marketing/community band): ~48–72 hours or “several days” is used to justify 2–3× weekly charts. No measured human PEG-MGF half-life was established by the primary and community material reviewed here; repeating the number does not validate it. forum
- PEG half-life claims (wider spread): ~24+ hours, multi-day, or ~5 days appear on different research-summary pages — treat as conflicting secondary claims, not a settled human PK parameter for every vendor lot. forum
- Dosing logic in charts: Claims of extended duration versus native MGF are used to favor less-than-daily PEG schedules, while minority charts describe daily use. Neither schedule establishes clearance, and the disagreement is not resolved by the borrowed half-life figures. forum
- Timing — default: Immediately or shortly post-workout (often within ~30 minutes in guides) on trained-muscle days to align with natural MGF-release storytelling. forum
- Timing — recovery days: Allowed in many charts (SubQ fine if not training); some prefer only hard training days. forum
- Vs IGF-1 LR3 timing lore: PEG soon post-workout for early “proliferation / satellite-cell” coverage; LR3 ~4–8 hours later, next day, or on alternate days for “differentiation / protein synthesis” coverage — complementary two-wave story, not a proven sequence trial. forum
- Vs native MGF + PEG combo: Some advanced logs still add short MGF post-workout plus PEG “coverage”; others call native+PEG redundant and wasteful. forum
- Vs IGF-1 DES: DES = short local burst IM; PEG-MGF = longer coverage with more systemic spillover talk — different tools. forum
- Food: Food-independent relative to oral peptides; some IM guides casually note large meals around injection may change local blood flow — minor lore, not a hard rule. forum
- Layering lore: Multi-day overlap is the stated intention behind 2–3×/week schedules. Actual persistence and overlap are not established for a verified human PEG-MGF product; a schedule is not a PK measurement. forum
More on what it is
- What it is: PEGylated Mechano Growth Factor is a community label for a polyethylene-glycol-modified MGF E-domain peptide. Native MGF/IGF-1Ec is discussed in local muscle responses to mechanical load or injury, but the synthetic MGF-24aa-E fragment is not the entire splice variant or full-length PEG-IGF-1. It remains a research/gray-market peptide, not an FDA-approved physique drug; a label does not verify its fragment or PEG structure. forum
- Native MGF vs PEG: Unmodified MGF (and the synthetic MGF-E / C-terminal E-domain peptide) is discussed as an ultra-short local repair signal; PEGylation is the bro fix so you do not need near-constant re-injection. forum
- Why people search it: Longer coverage than native MGF for post-training repair and satellite-cell proliferation talk, with fewer weekly pins than short-acting MGF protocols. forum
- Identity caveat: “PEG-MGF” on a research-chem label does not guarantee correct PEGylation, purity, or that the payload matches published MGF-E sequences — COAs and identity testing are ideal, not guaranteed. forum
- Mechanism talk: MGF / MGF-E lore = early activation and proliferation of muscle satellite (stem) cells (Pax7+ framing in research write-ups) without immediately forcing full differentiation; PEG version is sold as the same early signal with multi-day presence. Downstream IGF1R / repair-pathway storytelling is common; metabolic “insulin-like” load is usually framed as milder than IGF-1 LR3 but not zero. forum
- Evidence posture: Preclinical and cell work on MGF / MGF-E (satellite-cell proliferation, injury/loading expression) is denser than human RCTs for gray-market PEG-MGF physique use — vendor and protocol pages openly say no validated human dose-finding trials. animal
- What it is not: Not HGH, not insulin, not IGF-1 LR3, not IGF-1 DES, not native short-acting MGF (unless the vial is mislabeled), not a SARM, not an approved therapy for muscle growth or injury. trial
Stacks
- + IGF-1 LR3 (top pairing): “Two-wave” lore — PEG-MGF immediately post-workout for early satellite-cell / proliferation talk; LR3 hours later (~4–8 h), next morning, or on alternate days for sustained hypertrophy/protein-synthesis talk. Sample forum sketches vary widely (e.g., PEG ~150–250 mcg PWO days; LR3 ~10–50 mcg class bands on their own charts). Evidence is community-level; glucose vigilance rises with LR3. forum
- Alternate-day PEG vs LR3: Older board schedules sometimes alternate PEG days and LR3 days across a short block (including short 10-day alternating MGF/LR3 style protocols in modern blogs) — schedules conflict across camps. forum
- + IGF-1 DES: Short local DES site shots with longer PEG coverage — complexity and cost stack; advanced/confounded. forum
- + native (non-PEG) MGF: Short post-workout MGF plus PEG “blanket”; some guides call this redundant because PEG is already the long MGF. forum
- + HGH / somatropin: GH-axis growth/recovery stack — dual attribution; more growth-pathway load. forum
- + CJC-1295 (often no DAC) + Ipamorelin: Secretagogue pulse support upstream while PEG covers post-training repair lore; timing usually separated (GHS AM/bed fasted patterns vs PEG PWO). forum
- + Sermorelin / Tesamorelin: Alternate GHRH-class partners in modern peptide stacks (tesamorelin also appears in small app co-report lists). forum
- + MK-677: Oral GH-secretagogue + PEG — appetite/water from MK plus any PEG nonspecifics; confounded recomp/recovery talk. forum
- + BPC-157 (± TB-500 / “Wolverine” style): Soft-tissue / systemic healing peptides with muscle-specific PEG lore — popular recovery stack; different pathways, credit split. forum
- + GHK-Cu / NAD+: Appears in some modern tracker co-reports and wellness stacks — not classic 2010s bodybuilding core. forum
- + Retatrutide / GLP-1 class (emerging co-reports): Appetite suppression can mask hypo hunger cues if any IGF-family partner is present; extra vigilance lore if stacked for recomp. forum
- AAS bulks: PEG layered onto steroid cycles in advanced camps — multi-drug confounds dominate outcome claims. forum
- Training + surplus + protein: Progressive overload, calories, and sleep are repeatedly credited when logs look good — non-pharmacologic half of the stack. forum
- Insulin caution: Additive hypoglycemia risk if combined with insulin or aggressive IGF-1 LR3 — advanced/high-risk territory in forum lore. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection-site reactions (most common): Redness, warmth, itching, swelling, tenderness, small bumps, or burning — usually resolves within ~24–48 hours; rotate sites and improve technique. forum
- Persistent / spreading site reactions: Reactions lasting >48–72 hours, worsening, or looking infected are community stop-and-evaluate flags. forum
- Nausea: Mild nausea at higher doses appears in research-summary side lists. forum
- Headache: Early-week mild headaches in minority logs; hydration/rest lore; unresolved headaches after the first week are reassess triggers. forum
- Fatigue / flu-like feel: Temporary tiredness, muscle aches, or low-grade “flu-like” notes after injections in minority reports. anecdote
- Dizziness / lightheadedness: Less common; monitor context (hydration, glucose, BP). forum
- Blood-pressure talk: Occasional “monitor if hypertensive” notes on protocol pages — not a well-quantified trial endpoint for PEG-MGF. forum
- Hypoglycemia caution: IGF-family signaling lore; risk framed as lower than IGF-1 LR3/insulin for many users but not zero — extra caution if diabetes-prone, on insulin/secretagogues, or stacked with LR3. forum
- Blood-sugar fluctuations: Less-common community note; reassess dose/stack if glucose feels unstable. forum
- Water retention / joint stiffness: Occasional self-reports of temporary water feel or joint stiffness — causality muddy. anecdote
- Uneven / local hypertrophy talk: Theoretical risk of preferential local growth with aggressive repeated site IM — lore-level, not measured incidence. forum
- Desensitization lore: Unbroken multi-month use framed as less efficient over time — drives cycling culture more than gym-user receptor assays. forum
- Allergy / hypersensitivity: Rare severe allergic reactions are emergency-care territory if swelling, breathing difficulty, or systemic rash appear. forum
- IM technique risks: Nerve/vessel injury, deeper infection, and worse post-injection pain than SubQ if technique is poor. forum
- Source quality: Mislabeling, underdosing, contamination, wrong peptide, or incomplete PEGylation — structural gray-market risk independent of mechanism. forum
- Pregnancy / nursing / major illness: Community and cautious protocol language treat these as avoid-without-specialist-care zones. forum
- Drug interaction cautions (protocol pages): Extra caution with insulin/diabetes meds (glucose), anticoagulants (bruising), NSAIDs/corticosteroids (healing-process confound) — checklist-level, not PEG-MGF RCTs. forum
- Mitogenic / malignancy pathway caution: Growth-factor / IGF-axis signaling is proliferation- and anti-apoptosis–related; active or recent cancer, unexplained lumps, or proliferative disease are hard avoid zones in cautious write-ups. trial
- Legal / sport status: Research-only labeling common; regulatory posture varies by jurisdiction; IGF/MGF-class growth factors sit in prohibited peptide-hormone territory for tested sport (WADA S2 class logic) — athletes should assume risk. trial
- Not risk-free: Missing a side effect in one log ≠ safety evidence; research-chemical framing does not erase sterility, growth-pathway, or product-identity risks. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.